Transgene SA(TNG)

Description: Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

---

Keywords: Medicine Biotechnology Cancer Solid Tumors Infectious Diseases Treatment Of Cancer Ovarian Cancer Virotherapy Head And Neck Cancer Viruses Oncolytic Virus Treatment Of Ovarian Cancer Human Papilloma Virus Human Papillomavirus Infection Valneva Se Experimental Cancer Treatments Chronic Hepatitis B Transgene Sa Pexastimogene Devacirepvec Sillajen Hpv Positive Cancers Oncolytic Adenovirus Pexa Vec Tg6002 Treatment Of Hpv Positive Cancers

---

Home Page: www.transgene.fr

400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405
France
Phone: 33 3 88 27 91 00

---

Officers

Exchange: PA

Country: FR : France

Currency: Euro (€)